🔓
Sign in as a Member to unlock the full view of HR.10770. · Full carveout list, all affected companies, party defectors, and 30-day trade predictions.
Become a Member$29.99/mo already a Member? Sign in →
HR.10770 · 119TH CONGRESS

340B Rebate Model Delay Act

Status
In Committee
Latest Action
2026-10-09
Sponsor
Bresnahan, Robert P. (R-Pennsylvania)
Official Source
Investability
0/100
Stage
COMMITTEE
Related Bills
0
Full Text
Unavailable
Alive
Yes

What This Bill Does · Plain English

Summary · Congress.gov
340B Rebate Model Delay Act This bill temporarily limits the use of rebates for prescription drugs under the 340B program and delays the implementation of the 340B Rebate Model Pilot Program. Under current law, the 340B program generally limits the maximum price drug manufacturers participating in Medicaid or Medicare can charge eligible health care organizations for covered outpatient drugs. Beginning on January 1, 2027, and ending on December 31, 2028, the bill prohibits drug manufacturers from entering agreements with 340B organizations that require the organization to pay more than the allowable ceiling price for a covered outpatient drug at the time of purchase and subsequently receive a rebate to comply with the maximum price requirements. The bill also delays until January 1, 2029, the implementation of the 340B Rebate Model Pilot Program. The pilot program allows approved drug manufacturers to charge 340B organizations full price for certain high-impact drugs and provide a rebate that reduces the amount paid to the allowable ceiling price after the drug is dispensed. Under the pilot program, the rebates are verified and issued on a claim-by-claim basis.

Action Timeline

2026-10-09
Introduced in House
2026-10-09
Referred to the House Committee on Energy and Commerce.
2026-10-09
Introduced in House

Frequently Asked Questions

Did HR.10770 pass?
HR.10770 is still alive. Current stage: COMMITTEE. Pass likelihood: pending.
What does HR.10770 do?
340B Rebate Model Delay Act This bill temporarily limits the use of rebates for prescription drugs under the 340B program and delays the implementation of the 340B Rebate Model Pilot Program. Under current law, the 340B program generally limits the maximum price drug manufacturers participating in Medicaid or Medicare can charge eligible health care organizations for covered outpatient drugs. Beginning on January 1, 2027, and ending on December 31, 2028, the bill prohibits drug manufacturers from entering agreements with 340B organizations that require the organization to pay more than the all…
Who sponsored HR.10770?
HR.10770 was sponsored by Robert P. Bresnahan (R-Pennsylvania).

Full Bill Text

Full text not yet indexed for this bill. Check Congress.gov for the official text.
🔒 GovGreed Pro · Trading Intelligence on HR.10770 Get Access — $29.99/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated 2026-11-17. Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records. GovGreed is not affiliated with the U.S. Government. Not financial advice. [live render]